医学
社区获得性肺炎
肺炎
内科学
观察研究
抗生素
逻辑回归
抗生素治疗
重症监护医学
联合疗法
析因分析
前瞻性队列研究
多元分析
生物
微生物学
作者
José Manuel Pereira,João Gonçalves-Pereira,Óscar Ribeiro,João Pedro Baptista,Filipe Froes,José Artur Paiva
标识
DOI:10.1016/j.jcrc.2017.08.048
摘要
Antibiotic therapy (AT) is the cornerstone of the management of severe community-acquired pneumonia (CAP). However, the best treatment strategy is far from being established. To evaluate the impact of different aspects of AT on the outcome of critically ill patients with CAP, we performed a post hoc analysis of all CAP patients enrolled in a prospective, observational, multicentre study. Of the 502 patients included, 76% received combination therapy, mainly a β-lactam with a macrolide (80%). AT was inappropriate in 16% of all microbiologically documented CAP (n=177). Hospital and 6months mortality were 34% and 35%. In adjusted multivariate logistic regression analysis, combination AT with a macrolide was independently associated with a reduction in hospital (OR 0.17, 95%CI 0.06-0.51) and 6months (OR 0.21, 95%CI 0.07-0.57) mortality. Prolonged AT (>7days) was associated with a longer ICU (14 vs. 7days; p<0.001) and hospital length of stay (LOS) (25 vs. 17days; p<0.001). Combination AT with a macrolide may be the most suitable AT strategy to improve both short and long term outcome of severe CAP patients. AT >7days had no survival benefit and was associated with a longer LOS.
科研通智能强力驱动
Strongly Powered by AbleSci AI